ArticleCancer biomarkers : section A of Disease markers2017
Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor.
Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Epigenome-wide association study of blood proteome in the Atherosclerosis Risk in Communities study.HGG advances · 2026Article
- Development of a novel anti-erythropoietin-producing hepatocellular receptor B6 monoclonal antibody EbBiochemistry and biophysics reports · 2025Article
- Establishing a prognostic model with immune-related genes and investigating EPHB6 expression pattern in breast cancer.Scientific reports · 2025Article
- Erythropoietin-producing hepatocellular receptor B6 is highly expressed in non-functioning pituitary neuroendocrine tumors and its expression correlates with tumor size.Molecular biology reports · 2024Article
- Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers.Frontiers in oncology · 2024Review
- The role of EphA7 in different tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- A Novel Pyroptosis-Related Prognostic Signature for Cervical Squamous Cell Carcinoma.International journal of general medicine · 2022Article
- Role and mechanism of miR-211 in human cancer.Journal of Cancer · 2022Review
- An integrated analysis of DNA promoter methylation, microRNA regulation, and gene expression in gastric adenocarcinoma.Annals of translational medicine · 2021Article
- The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread.International journal of molecular sciences · 2021Review
- Structure of the EphB6 receptor ectodomain.PloS one · 2021Article
- Status of kinases in Epstein-Barr virus and Helicobacter pylori Coinfection in gastric Cancer cells.BMC cancer · 2020Article
Corrections and comments
- Retracted
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEph receptors comprise the largest group of the receptor tyrosine kinase (RTK) family, and Eph receptors interacting with their ligand ephrins play an important role in development and tumorigenesis. EphB6, a special Eph receptor that lacks tyrosine kinase activity, was reported to be expressed in some human cancers. The clinical significance of EphB6 in gastric carcinoma has not been well investigated.
methodsIn this study, we detected expression of EphB6 protein in four gastric cancer cell lines and a set of gastric carcinoma tissue specimens by using immunohistochemistry. The relationship between EphB6 protein expression and clinicopathological parameters was statistically analyzed.
resultsEphB6 protein was differentially detected in four gastric cancer cell lines. EphB6 protein was low expressed in 52.6%, moderately expressed in 32.59%, and strongly expressed in 14.5% of gastric carcinomas. EphB6 expression was positively associated with tumor differentiation (P< 0.001, rs= 0.476), and negatively associated with lymph node metastasis (P< 0.001, rs=-0.444) and tumor stage (P= 0.001, rs=-0.269). Low EphB6 expression was detected more often in female patients (P= 0.031). No significant relationship between EphB6 expression and patient age, tumor location, or depth of tumor invasion was identified.
conclusionOur data indicate that EphB6 protein was decreased in gastric carcinoma compared with normal mucosa. Analytic results based on pathological parameters suggests that EphB6 protein may inhibit metastasis of gastric carcinoma and could be a potential therapeutic target for gastric carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.